Based on the Paradigm Biopharmaceuticals Ltd stock forecast from 0 analysts, the average analyst target price for Paradigm Biopharmaceuticals Ltd is not available over the next 12 months. Paradigm Biopharmaceuticals Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Paradigm Biopharmaceuticals Ltd is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Paradigm Biopharmaceuticals Ltd’s stock price was AUD 0.38. Paradigm Biopharmaceuticals Ltd’s stock price has changed by -1.32% over the past week, +33.93% over the past month and +1.35% over the last year.
No recent analyst target price found for Paradigm Biopharmaceuticals Ltd
No recent average analyst rating found for Paradigm Biopharmaceuticals Ltd
Company Overview Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. Read Less
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river vir...Read More
Frequently Asked Questions About Paradigm Biopharmaceuticals Ltd (PAR:AU) Stock
Stock Target Advisor's fundamental analysis for Paradigm Biopharmaceuticals Ltd's stock is Bearish.
Unfortunately we do not have enough data on PAR:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PAR:AU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PAR:AU's stock to indicate if its overvalued.
The last closing price of PAR:AU's stock was AUD 0.38.
The most recent market capitalization for PAR:AU is AUD 0.18B.
Unfortunately we do not have enough analyst data on PAR:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Paradigm Biopharmaceuticals Ltd's stock.
As per our most recent records Paradigm Biopharmaceuticals Ltd has 0 Employees.
Paradigm Biopharmaceuticals Ltd's registered address is 500 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Paradigm Biopharmaceuticals Ltd's website at https://www.paradigmbiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Paradigm Biopharmaceuticals Ltd (PAR:AU) Stock
Stock Target Advisor's fundamental analysis for Paradigm Biopharmaceuticals Ltd's stock is Bearish.
Unfortunately we do not have enough data on PAR:AU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PAR:AU's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on PAR:AU's stock to indicate if its overvalued.
The last closing price of PAR:AU's stock was AUD 0.38.
The most recent market capitalization for PAR:AU is AUD 0.18B.
Unfortunately we do not have enough analyst data on PAR:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Paradigm Biopharmaceuticals Ltd's stock.
As per our most recent records Paradigm Biopharmaceuticals Ltd has 0 Employees.
Paradigm Biopharmaceuticals Ltd's registered address is 500 Collins Street, Melbourne, VIC, Australia, 3000.
You can get more information about it from Paradigm Biopharmaceuticals Ltd's website at https://www.paradigmbiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PAR:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
